Menopause — MCQs

Menopause Indian Medical PG Practice Questions and MCQs

Question 51: What is an absolute contraindication to hormone replacement therapy?

A. Osteoporosis
B. Otosclerosis (Correct Answer)
C. Colon cancer
D. Premature menopause

Explanation: **Explanation:** The correct answer is **Otosclerosis**. In the context of Hormone Replacement Therapy (HRT), it is crucial to distinguish between indications, relative contraindications, and absolute contraindications. **Why Otosclerosis is the Correct Answer:** Otosclerosis is a condition characterized by abnormal bone remodeling in the middle ear. Estrogen is known to accelerate the progression of otosclerotic lesions, potentially leading to rapid and irreversible conductive hearing loss. Therefore, it is considered an **absolute contraindication** to HRT. **Analysis of Incorrect Options:** * **Osteoporosis:** This is a primary **indication** for HRT. Estrogen inhibits osteoclast activity, reducing bone resorption and the risk of fractures in postmenopausal women. * **Colon Cancer:** HRT (specifically combined estrogen-progestogen therapy) is actually associated with a **decreased risk** of colorectal cancer. It is not a contraindication. * **Premature Menopause:** This is a strong **indication** for HRT. Women with premature ovarian insufficiency (POI) require HRT until at least the average age of natural menopause (approx. 51 years) to prevent cardiovascular disease and osteoporosis. **High-Yield Clinical Pearls for NEET-PG:** * **Absolute Contraindications to HRT:** Undiagnosed abnormal vaginal bleeding, known or suspected pregnancy, active thromboembolic disease (DVT/PE), active liver disease, and estrogen-dependent tumors (e.g., Breast or Endometrial cancer). * **Otosclerosis & Pregnancy:** Hearing loss in otosclerosis often worsens during pregnancy due to high endogenous estrogen levels. * **Gold Standard for Vasomotor Symptoms:** HRT remains the most effective treatment for "hot flashes" and "night sweats." * **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60.

Question 52: All of the following agents are used in the treatment of hot flashes, EXCEPT?

A. Tamoxifen (Correct Answer)
B. Venlafaxine
C. Gabapentin
D. Paroxetine

Explanation: **Explanation:** The management of vasomotor symptoms (hot flashes) in menopause involves both hormonal and non-hormonal therapies. **Why Tamoxifen is the Correct Answer:** **Tamoxifen** is a Selective Estrogen Receptor Modulator (SERM) used primarily in breast cancer treatment. It acts as an estrogen antagonist in the breast but as an agonist in other tissues. Crucially, Tamoxifen is well-known to **induce or worsen hot flashes** as a side effect rather than treating them. In contrast, Estrogen Replacement Therapy (ERT) is the gold standard for treating hot flashes, but Tamoxifen's anti-estrogenic effect on the hypothalamus triggers thermoregulatory instability. **Analysis of Other Options:** * **Venlafaxine (Option B):** A Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). It is a highly effective non-hormonal treatment for hot flashes, especially in breast cancer survivors who cannot take estrogen. * **Gabapentin (Option C):** An anti-convulsant that has been shown to significantly reduce the frequency and severity of hot flashes by modulating calcium channels in the hypothalamus. * **Paroxetine (Option D):** An SSRI. Low-dose Paroxetine is the only non-hormonal medication specifically **FDA-approved** for the treatment of moderate-to-severe vasomotor symptoms. **Clinical Pearls for NEET-PG:** * **Gold Standard Treatment:** Estrogen (HRT) is the most effective treatment for vasomotor symptoms. * **FDA-Approved Non-Hormonal:** Low-dose Paroxetine (7.5 mg). * **Clonidine:** A centrally acting alpha-2 agonist is also used but is generally considered second-line due to side effects like hypotension and dry mouth. * **Tibolone:** A synthetic steroid with estrogenic, progestogenic, and androgenic properties that also treats hot flashes.

Question 53: Vitamin H is useful in all except?

A. Flushing
B. Osteoporosis
C. Vaginal atrophy
D. Coronary heart disease (Correct Answer)

Explanation: **Explanation:** The term **"Vitamin H"** in the context of menopause is a clinical synonym for **Hormone Replacement Therapy (HRT)**, specifically Estrogen. Estrogen plays a critical role in maintaining various physiological functions that decline during the climacteric period. **1. Why "Coronary Heart Disease" is the correct answer:** According to the **Women's Health Initiative (WHI) study**, HRT (especially combined estrogen-progestogen therapy) does not provide primary or secondary protection against Coronary Heart Disease (CHD). In fact, if started late (more than 10 years after menopause or after age 60), it may **increase the risk** of thromboembolic events and stroke. Therefore, it is not considered a "useful" indication for preventing heart disease. **2. Analysis of Incorrect Options:** * **Flushing (Vasomotor Symptoms):** HRT is the **gold standard** treatment for hot flashes and night sweats. It stabilizes the thermoregulatory center in the hypothalamus. * **Osteoporosis:** Estrogen inhibits osteoclast activity. HRT is highly effective in preventing bone loss and reducing the risk of vertebral and hip fractures. * **Vaginal Atrophy:** Estrogen maintains the thickness and vascularity of the vaginal epithelium. Local or systemic HRT is the primary treatment for urogenital atrophy. **Clinical Pearls for NEET-PG:** * **Window of Opportunity Hypothesis:** HRT is safest and most effective when started within 10 years of menopause or before age 60. * **Indications:** Moderate-to-severe vasomotor symptoms, premature ovarian insufficiency (POI), and prevention of osteoporosis. * **Contraindications:** Undiagnosed vaginal bleeding, active liver disease, history of breast cancer, and history of DVT/PE. * **Drug of choice for night sweats in menopause:** HRT (Estrogen).

Question 54: FSH level above what value is considered diagnostic of menopause?

A. 20 IU/L
B. 25 IU/L
C. 30 IU/L (Correct Answer)
D. 35 IU/L

Explanation: ### Explanation **Correct Option: C (30 IU/L)** The diagnosis of menopause is primarily clinical, defined as **12 months of amenorrhea** in a woman over age 45. However, in cases of diagnostic uncertainty (e.g., premature ovarian insufficiency or post-hysterectomy), biochemical confirmation is required. The underlying pathophysiology involves the depletion of ovarian follicles, leading to a drastic fall in **Inhibin B** and **Estradiol**. The loss of negative feedback on the pituitary gland results in a compensatory rise in **Follicle Stimulating Hormone (FSH)**. A serum FSH level **>30 IU/L** (measured on two occasions, 4–6 weeks apart) is the standard diagnostic threshold for menopause. **Analysis of Incorrect Options:** * **A & B (20–25 IU/L):** These levels are often seen during the **perimenopausal transition** (climacteric). While elevated compared to the reproductive phase, they do not confirm permanent ovarian failure. * **D (35 IU/L):** While an FSH of 35 IU/L is indeed diagnostic, it is not the *minimum* threshold. In competitive exams like NEET-PG, the standard cutoff established by WHO and clinical guidelines is 30 IU/L. **High-Yield Clinical Pearls for NEET-PG:** * **Most sensitive initial marker:** A decrease in **Inhibin B** is the earliest biochemical change. * **Best marker for ovarian reserve:** **Anti-Müllerian Hormone (AMH)**; it remains stable throughout the menstrual cycle. * **Estrogen profile:** In menopause, **Estrone (E1)** becomes the dominant estrogen (via peripheral conversion of androstenedione in fat), replacing **Estradiol (E2)**. * **LH/FSH Ratio:** In menopause, both are elevated, but **FSH rises more significantly** than LH because FSH has a slower clearance rate.

Question 55: Hormone replacement therapy (HRT) is protective against which of the following?

A. Hip fracture (Correct Answer)
B. Breast cancer
C. Deep vein thrombosis (DVT)
D. Myocardial infarction (MI)

Explanation: **Explanation:** **1. Why Hip Fracture is Correct:** Estrogen plays a critical role in maintaining bone mineral density (BMD) by inhibiting osteoclast activity and reducing bone resorption. After menopause, the decline in estrogen leads to rapid bone loss. Hormone Replacement Therapy (HRT) effectively halts this process and has been clinically proven to reduce the risk of osteoporotic fractures, including **hip, vertebral, and wrist fractures**. According to the Women’s Health Initiative (WHI) study, HRT is one of the most effective treatments for preventing postmenopausal bone loss. **2. Why the Other Options are Incorrect:** * **Breast Cancer:** Long-term use of combined HRT (Estrogen + Progesterone) is associated with an **increased risk** of breast cancer. Estrogen-only therapy (in women without a uterus) has a more neutral or slightly lower risk profile, but HRT is never considered "protective" against it. * **Deep Vein Thrombosis (DVT):** Oral HRT increases the synthesis of clotting factors in the liver (first-pass metabolism), leading to a **higher risk** of venous thromboembolism (VTE) and DVT. * **Myocardial Infarction (MI):** While HRT may have a cardioprotective effect if started early (the "Timing Hypothesis"), the WHI study showed that starting combined HRT in older postmenopausal women actually **increases** the risk of coronary heart disease and stroke. **NEET-PG High-Yield Pearls:** * **Gold Standard Indication:** The primary indication for HRT is the management of moderate-to-severe **vasomotor symptoms** (hot flashes). * **The "Window of Opportunity":** HRT is safest when started within 10 years of menopause or before age 60. * **Uterine Status:** Always add Progesterone to Estrogen if the patient has an intact uterus to prevent **Endometrial Carcinoma**. * **Colorectal Cancer:** Interestingly, combined HRT is also associated with a **decreased risk** of colorectal cancer.

Question 56: What is the typical volume of an ovary after menopause?

A. 8 cm2
B. 5 cm2
C. 4 cm2
D. 3 cm2 (Correct Answer)

Explanation: **Explanation:** The size and volume of the ovary are dynamic throughout a woman’s life, primarily influenced by hormonal activity and the presence of follicles. **1. Why Option D (3 cm³) is Correct:** After menopause, the cessation of follicular development and the depletion of the oocyte pool lead to significant ovarian atrophy. The ovaries shrink, become sclerotic, and lose their characteristic convoluted surface. In a postmenopausal woman, the typical ovarian volume is **less than 5 cm³**, with **3 cm³** being the most representative average value cited in standard textbooks (like Williams Gynecology). A volume greater than 8 cm³ in a postmenopausal woman is considered clinically suspicious and warrants further investigation. **2. Analysis of Incorrect Options:** * **Option A (8 cm³):** This is the average volume of a healthy, functioning ovary in a **reproductive-age woman**. It is too large for a postmenopausal state. * **Option B (5 cm³):** This is often considered the upper limit of normal for a postmenopausal ovary. While closer, it represents the threshold for concern rather than the "typical" atrophied volume. * **Option C (4 cm³):** While some postmenopausal ovaries may be this size, 3 cm³ is the more classically taught "typical" volume for the NEET-PG curriculum. **3. High-Yield Clinical Pearls for NEET-PG:** * **PMPO Syndrome (Postmenopausal Palpable Ovary):** In a postmenopausal woman, the ovaries should not typically be palpable on bimanual examination. A palpable ovary in this age group is considered an "early warning sign" of potential malignancy until proven otherwise. * **Premenopausal Volume:** 6–10 cm³ (Average 8 cm³). * **Postmenopausal Volume:** < 5 cm³ (Average 3 cm³). * **Rule of Thumb:** Any ovary in a postmenopausal woman that is twice the size of the contralateral ovary, even if within "normal" limits, should be investigated.

Question 57: The symptoms of menopause are best treated with what medication?

A. Oestrogen (Correct Answer)
B. Progesterone
C. Testosterone
D. Clomiphene

Explanation: **Explanation:** The primary physiological change in menopause is the **depletion of ovarian follicles**, leading to a significant decline in circulating **oestrogen** levels. This hypoestrogenic state is directly responsible for the classic symptoms of menopause, such as vasomotor instability (hot flashes, night sweats), urogenital atrophy, and mood disturbances. Therefore, **Oestrogen** is the most effective treatment for alleviating these symptoms (Hormone Replacement Therapy - HRT). **Analysis of Options:** * **A. Oestrogen (Correct):** It addresses the root cause of menopausal symptoms. In women with an intact uterus, oestrogen must be combined with progesterone to prevent endometrial hyperplasia/carcinoma. In women post-hysterectomy, oestrogen-only therapy is the standard. * **B. Progesterone:** While used in HRT, its primary role is **endometrial protection** against the stimulatory effects of oestrogen. It is not the primary agent for symptom relief. * **C. Testosterone:** Sometimes used off-label for hypoactive sexual desire disorder (HSDD) in postmenopausal women, but it is not the first-line treatment for general menopausal symptoms. * **D. Clomiphene:** An Estrogen Receptor Modulator (SERM) used primarily for **ovulation induction** in infertility; it can actually worsen vasomotor symptoms (hot flashes). **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard:** HRT is the most effective treatment for vasomotor symptoms. * **Indication:** The primary indication for HRT is symptomatic relief, not the prevention of chronic diseases (like CHD). * **Window of Opportunity:** HRT is safest when started in women <60 years old or within 10 years of menopause onset. * **Non-Hormonal Alternative:** **SSRIs/SNRIs** (e.g., Paroxetine) or **Gabapentin** are the drugs of choice for vasomotor symptoms in women with contraindications to oestrogen (e.g., history of breast cancer).

Question 58: A 33-year-old female presents with a 6-month history of amenorrhea. Biochemical investigations showed increased FSH and decreased estradiol. What is the most likely diagnosis?

A. Polycystic Ovarian Disease (PCOD)
B. Hyperprolactinemia
C. Premature menopause (Correct Answer)
D. Ectopic pregnancy

Explanation: ### Explanation **Correct Answer: C. Premature menopause** The clinical presentation of a woman under 40 years of age with amenorrhea for >4 months, associated with **elevated FSH (>40 IU/L)** and **low estradiol**, is diagnostic of **Premature Ovarian Failure (POF)**, also known as **Premature Menopause**. The underlying pathophysiology is the depletion of the ovarian follicle pool or follicular resistance. Due to the lack of negative feedback from estrogen and inhibin-B (produced by follicles), the pituitary gland secretes excessively high levels of Follicle Stimulating Hormone (FSH) in an attempt to stimulate the ovaries. **Analysis of Incorrect Options:** * **A. PCOD:** Characterized by hyperandrogenism and polycystic morphology on ultrasound. Hormonally, it typically shows an **increased LH:FSH ratio (2:1 or 3:1)**, not elevated FSH. * **B. Hyperprolactinemia:** High prolactin levels inhibit GnRH pulsatility, leading to low or normal FSH and LH (**Hypogonadotropic Hypogonadism**). * **D. Ectopic Pregnancy:** Presents with amenorrhea and abdominal pain. The biochemical marker is **elevated β-hCG**, not FSH. **High-Yield Clinical Pearls for NEET-PG:** * **Definition:** Menopause occurring before the age of **40 years**. * **Gold Standard Diagnostic:** Two readings of serum FSH >40 IU/L (some guidelines use >25-30 IU/L) taken at least 4 weeks apart. * **Most Common Karyotype Abnormality:** Turner Syndrome (45,XO) or Mosaicism (45,X/46,XX). * **Fragile X Premutation:** The most common known genetic cause of "sporadic" premature menopause. * **Management:** Hormone Replacement Therapy (HRT) is mandatory until the age of natural menopause (approx. 50 years) to prevent osteoporosis and cardiovascular disease.

Question 59: Which among the following is the treatment of choice for senile vaginitis?

A. Oral pills
B. Nystatin locally
C. Estrogen cream (Correct Answer)
D. Ketoconazole

Explanation: **Explanation:** **Senile vaginitis** (also known as Atrophic Vaginitis) occurs due to the withdrawal of estrogen following menopause. Estrogen is essential for maintaining the thickness of the vaginal epithelium and the acidity of the vaginal pH (via glycogen production and *Lactobacillus* colonization). In its absence, the vaginal mucosa becomes thin, dry, and prone to inflammation and secondary infections. **Why Estrogen Cream is the Correct Answer:** The treatment of choice is **local (topical) estrogen therapy**. Estrogen cream directly restores the vaginal epithelium, improves vascularity, and re-establishes the normal acidic pH. Local administration is preferred over systemic therapy because it provides rapid relief of symptoms with minimal systemic absorption, thereby reducing the risk of endometrial hyperplasia or thromboembolism. **Analysis of Incorrect Options:** * **A. Oral pills:** While systemic Hormone Replacement Therapy (HRT) can treat vaginal atrophy, it is not the "treatment of choice" for isolated vaginal symptoms due to the higher risk profile compared to local application. * **B. Nystatin locally:** This is an antifungal used for *Candidiasis*. While senile vaginitis increases infection risk, Nystatin does not address the underlying hormonal deficiency. * **D. Ketoconazole:** This is an antifungal agent. It is ineffective against the primary cause of atrophic vaginitis, which is hypoestrogenism. **High-Yield Clinical Pearls for NEET-PG:** * **Cytology:** A vaginal smear in senile vaginitis typically shows a high **Maturation Index** shift to the left (predominance of **parabasal cells** and absence of superficial cells). * **pH Change:** Vaginal pH rises from the normal 4.5 to **6.0–7.0** in menopause. * **First-line for mild symptoms:** Non-hormonal vaginal moisturizers and lubricants. * **Safety:** Local estrogen does not generally require progestogen cover for endometrial protection, unlike systemic estrogen.

Question 60: All of the following are advantages of using raloxifene over estrogen in post-menopausal women EXCEPT?

A. Reduces fracture rates
B. Avoids endometrial hyperplasia
C. Reduces incidence of venous thrombosis (Correct Answer)
D. No increase in incidence of breast carcinoma

Explanation: **Explanation:** The question asks for the **exception** regarding the advantages of Raloxifene over Estrogen. The correct answer is **C (Reduces incidence of venous thrombosis)** because both Estrogen and Raloxifene actually **increase** the risk of Venous Thromboembolism (VTE). **1. Why Option C is the correct answer (The Exception):** Raloxifene is a Second Generation **Selective Estrogen Receptor Modulator (SERM)**. While it acts as an antagonist in the breast and uterus, it acts as an **agonist** on the liver's coagulation pathways. Consequently, like conventional Estrogen Therapy (ET), Raloxifene increases the risk of deep vein thrombosis (DVT) and pulmonary embolism. Therefore, it offers no advantage over estrogen regarding thrombotic safety. **2. Why other options are incorrect (Advantages of Raloxifene):** * **A. Reduces fracture rates:** Raloxifene has an estrogenic (agonist) effect on bone, increasing bone mineral density and significantly reducing the risk of vertebral fractures. * **B. Avoids endometrial hyperplasia:** Unlike estrogen (which causes endometrial proliferation), Raloxifene acts as an **antagonist** in the uterus. It does not cause hyperplasia or uterine cancer, eliminating the need for progestogen co-administration. * **D. No increase in breast carcinoma:** Raloxifene acts as an **antagonist** in breast tissue. It is FDA-approved for the prevention of invasive breast cancer in high-risk postmenopausal women. **High-Yield Clinical Pearls for NEET-PG:** * **Raloxifene Summary:** Agonist on **Bone** and **Lipids**; Antagonist on **Breast** and **Endometrium**. * **Side Effects:** Most common side effects are **hot flashes** (it can worsen menopausal vasomotor symptoms) and leg cramps. * **Tamoxifen vs. Raloxifene:** Tamoxifen is an agonist on the endometrium (increases cancer risk), whereas Raloxifene is an antagonist (safe for the endometrium). * **Contraindication:** History of VTE is a strict contraindication for both Estrogen and Raloxifene.

Practice by Chapter

Physiology of Menopause

Practice Questions

Perimenopausal Transition

Practice Questions

Menopausal Symptoms and Management

Practice Questions

Hormone Replacement Therapy

Practice Questions

Non-hormonal Management Options

Practice Questions

Osteoporosis Prevention and Management

Practice Questions

Cardiovascular Health in Menopause

Practice Questions

Urogenital Atrophy

Practice Questions

Psychological Aspects of Menopause

Practice Questions

Premature Menopause

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?